Mifepristone for Patients With Endometrial Cancer and LGESS (NCT00505739) | Clinical Trial Compass
CompletedPhase 2
Mifepristone for Patients With Endometrial Cancer and LGESS
United States13 participantsStarted 2001-09
Plain-language summary
Primary Objectives:
1. To determine the antitumor activity of Mifepristone (RU-486) in patients with advanced or recurrent endometrioid adenocarcinoma or low grade endometrial stromal sarcoma (LGESS).
2. To evaluate the quantitative and qualitative toxicities of Mifepristone in this patient population.
3. To evaluate at a tissue level the effect of Mifepristone on estrogen and progesterone receptors post treatment and to evaluate other markers that may reflect effects of Mifepristone on cancer cell growth.
4. To evaluate the effect of the agent and dosing schedule on the patient's quality of life.
Who can participate
SexFEMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Histologic diagnosis of advanced/recurrent endometrioid adenocarcinoma or low grade endometrial stromal sarcoma (LGESS) not amenable to curative surgery or radiotherapy.
✓. Patients should have previously undergone radical surgery (minimum of total abdominal hysterectomy and bilateral salpingoophorectomy) definitive radiation therapy, or not be candidates for such procedures.
✓. The primary (including archived specimens) or recurrent tumor must be PR positive. Hormone receptor positivity is defined as PR positivity in \>/+10% cells by immunohistochemistry.
✓. Prior radiotherapy must have been completed at least 2 weeks prior to the initiation of Mifepristone and patients must have recovered from the acute side effects of such treatment.
✓. Performance status \< Zubrod 2.
✓. Estimated life expectancy of at least 12 weeks.
✓. Prior chemotherapy for recurrent or metastatic endometrial cancer is permitted.
✓. Patients must have measurable disease as defined by the presence of bidimensionally measurable lesions with clearly defined margins on x-ray, scan (CT or MRI) or physical exam.
Exclusion criteria
What they're measuring
1
Number of Patients with Overall Response
Timeframe: With each 4 week cycle, follow up 2 years
. Patients with serous or clear cell carcinomas of the endometrium.
✕. Patients whose tumor is known to be PR negative.
✕. Uncontrolled hypercalcemia.
✕. Patients taking phenytoin, phenobarbital or carbamazepine.
✕. Known predisposition to thromboembolic disorder, which in the investigator's judgment would put the patient at unacceptable risk for thromboembolic complications.
✕. Patients who have received treatment for brain metastases may be enrolled provided they have remained stable for at least 6 months after surgery or radiation.
✕. Women taking estrogen, progestin or antiprogestins. Patients taking these drugs must have discontinued their use at least 3 weeks prior to beginning treatment with Mifepristone.
✕. History of other malignancy (except adequately treated non-melanomatous carcinoma of the skin or cervical carcinoma in situ) unless in complete remission and off all therapy for that disease for a minimum of 5 years.